Latest Capricor Therapeutics News & Updates

See the latest news and media coverage for Capricor. We track all announcements, press releases, and industry mentions in real time, all in one place.

Capricor Therapeutics (Capricor)

Biotechnology company developing cell and exosome-based therapeutics

capricor.com

Headquarters: San Diego, United States
Founded year: 2005
Company type: Public company
Number of employees: 200–280
Industry: Pharmaceuticals

Last updated October 21

Latest news about Capricor Therapeutics (Capricor)

In short: Capricor’s Deramiocel review was extended to November 2026 after it submitted additional data.

Company announcements

October 5 Capricor

Capricor updates Deramiocel BLA status and HOPE-3 data

The FDA decision date is extended to Nov 22, 2026. The company submitted a major amendment with new robustness analyses and an Integrated Summary of Efficacy.

August 13 Capricor

Capricor reports Q2 2026 financial results and Deramiocel update

Cash at $238M, net loss widened to $40.7M, FDA advisory committee voted against, but HOPE-3 published in The Lancet.

August 10 Capricor

Capricor Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

The biotech reports a net loss of $40.7 million while advancing Deramiocel's BLA review with significant clinical data published in The Lancet.

July 29 Capricor

Capricor announces publication of HOPE-3 data in The Lancet

The peer-reviewed results show a 54% slowing of upper limb decline and cardiac benefit in Duchenne patients.

Media coverage

October 21 StockTwits

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

According to data from Koyfin, four of the 10 analysts covering CAPR rate it Buy or higher, while six rate it Hold. Advertisement|Remove ads. Shares...

October 19 CGTLive

FDA Extends Deramiocel Review for Duchenne Muscular Dystrophy | CGTlive®

What is deramiocel being developed for? Deramiocel is an investigational allogeneic cardiosphere-derived cell therapy being developed by Capricor Therapeutics to treat Duchenne muscular dystrophy, with...

October 3 StreetInsider

Capricor's DMD drug slows upper limb decline in 24-month study

Capricor Therapeutics (NASDAQ: CAPR) presented data from the HOPE-3 open-label extension study showing that patients with Duchenne muscular dystrophy (DMD) who switched from placebo to...

September 29 Seeking Alpha

Capricor jumps as study shows longer-term effects of deramiocel

The longer-term findings build on the randomized 12-month HOPE-3 results. The Phase 3 study met its primary endpoint, with deramiocel slowing deterioration in upper-limb function...

Never miss news about Capricor

Track Capricor and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Capricor competitors & trending companies

Browse news for competitors to Capricor and other trending companies.